236 related articles for article (PubMed ID: 9792584)
1. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.
Gupta N; Gill H; Graeber G; Bishop H; Hurst J; Stephens T
Chest; 1998 Oct; 114(4):1105-11. PubMed ID: 9792584
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of pulmonary lesions by parametric imaging in (18)F-FDG PET/CT dynamic multi-bed scanning.
Wang Q; Wang RF; Zhang J; Zhou Y
J BUON; 2013; 18(4):928-34. PubMed ID: 24344019
[TBL] [Abstract][Full Text] [Related]
4. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions.
Imdahl A; Jenkner S; Brink I; Nitzsche E; Stoelben E; Moser E; Hasse J
Eur J Cardiothorac Surg; 2001 Aug; 20(2):324-9. PubMed ID: 11463551
[TBL] [Abstract][Full Text] [Related]
5. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
10. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
[TBL] [Abstract][Full Text] [Related]
11. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
12. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract][Full Text] [Related]
13. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
[TBL] [Abstract][Full Text] [Related]
14. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
15. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
[TBL] [Abstract][Full Text] [Related]
16. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET.
Núñez R; Kalapparambath A; Varela J
Rev Esp Med Nucl; 2007; 26(4):196-207. PubMed ID: 17662186
[TBL] [Abstract][Full Text] [Related]
17. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
18. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
19. Differentiating benign and malignant pulmonary lesions with FDG-PET.
Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours.
Kang WJ; Chung JK; So Y; Jeong JM; Lee DS; Lee MC
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):202-7. PubMed ID: 15129702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]